SCHEMBL6001518

SCHEMBL6001518

Cc1ccc(CNc2cc(-c3cc(N4CCCCC4)ccc3NC(=O)c3cccc(CSCCC(=O)O)c3)ncn2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC34A2 O95436 1/20 0.40
▸ LOXL2 Q9Y4K0 2/20 0.38
▸ KIT P10721 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ ITK Q08881 1/20 0.37
▸ PARP1 P09874 1/20 0.37
▸ CYP1A2 P05177 4/20 0.36
▸ TSHR P16473 4/20 0.36
▸ CYP2C19 P33261 4/20 0.36
▸ CYP2D6 P10635 3/20 0.36
▸ MAPK1 P28482 3/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ CYP3A4 P08684 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40499 0.94 CYP1A2 (0.42) SLC34A2LOXL2KITSRCFLT3
SCHEMBL46438 0.93 LOXL2 (0.40) SLC34A2LOXL2KITSRCFLT3
SCHEMBL46550 0.91 SLC34A2 (0.40) SLC34A2LOXL2KITSRCFLT3
SCHEMBL46629 0.89 SLC34A2 (0.51) SLC34A2LOXL2CLK4ALDH1A1SMN1; SMN2
SCHEMBL19580001 0.89 SLC34A2 (0.52) SLC34A2LMNA
SCHEMBL46949 0.88 SLC34A2 (0.42) SLC34A2LOXL2CYP1A2TSHRCYP2C19
SCHEMBL46498 0.85 RAF1 (0.43) SLC34A2PARP1TP53SMN1; SMN2MAPK14
SCHEMBL39960 0.85 CYP1A2 (0.40) SLC34A2LOXL2KITSRCFLT3
SCHEMBL46747 0.85 SLC34A2 (0.41) SLC34A2PARP1TP53ALDH1A1SMN1; SMN2
SCHEMBL46430 0.83 SLC34A2 (0.47) SLC34A2SRCALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590656-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2017-11-15 — — EP claimed
EP-2590656-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2017-11-15 — — EP disclosed
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2017-02-09 — — US disclosed
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2017-02-09 — — US disclosed
EP-2591354-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2016-09-07 — — EP disclosed
US-9301951-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2016-04-05 — — US disclosed
US-9301951-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2016-04-05 — — US disclosed
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2015-06-18 — — US disclosed
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2015-06-18 — — US disclosed
US-8916569-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2014-12-23 — — US disclosed
US-8916569-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2014-12-23 — — US disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 — — US disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 — — US disclosed
WO-2012054110-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-04-26 — — WO disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A2, SLC34A1, SLC10A2 SLC34A2 1/4885LOXL2 4303/4885KIT 3194/4885
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A2, SLC34A1, SLC10A2 SLC34A2 1/4885LOXL2 4303/4885KIT 3194/4885
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC10A2, SLC34A2, SLC34A3 SLC34A2 2/4885LOXL2 4391/4885KIT 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback